- Home
- KALV vs NEO Comparison
KALV vs NEO Comparison
Compare KALV & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALV | NEO |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | 2008 |
Fundamental Metrics
Financial Performance| Metric | KALV | NEO |
|---|---|---|
| Price | $26.79 | $9.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $32.60 | $13.38 |
| AVG Volume (30 Days) | ★ 5.4M | 2.0M |
| Earning Date | 07-09-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | $185.42 | $10.63 |
| Revenue Next Year | $59.23 | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $4.72 |
| 52 Week High | $26.85 | $13.74 |
Technical Indicators
Market Signals| Indicator | KALV | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 60.46 |
| Support Level | $14.25 | $7.42 |
| Resistance Level | $26.85 | $10.82 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | -0.22 | 0.04 |
| Stochastic Oscillator | 71.05 | 89.45 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.